Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry
D. Jovanovic (Belgrade, Republic of Serbia), M. Šterclová (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), K. Lewandowska (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Hájková (Bratislava, Slovakia), M. Kramer (Petah Tikva, Israel), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Studnicka (Salzburg, Austria), . Stoeva (Sofia, Bulgaria), B. Jovkovska Kaeva (Skopje), S. Littnerová (Brno, Czech Republic), M. Roksandic Milenkovic (Belgrade, Republic of Serbia), M. Vašáková (Prague, Czech Republic)
Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Jovanovic (Belgrade, Republic of Serbia), M. Šterclová (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), K. Lewandowska (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Hájková (Bratislava, Slovakia), M. Kramer (Petah Tikva, Israel), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Studnicka (Salzburg, Austria), . Stoeva (Sofia, Bulgaria), B. Jovkovska Kaeva (Skopje), S. Littnerová (Brno, Czech Republic), M. Roksandic Milenkovic (Belgrade, Republic of Serbia), M. Vašáková (Prague, Czech Republic). Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry. 3391
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: